- •Foreword
- •Preface
- •Acknowledgements
- •Contents
- •Contributors
- •Summary: An Introduction to Mohs Micrographic Surgery
- •1.1 Introduction
- •Summary: Conclusion
- •1.2 Conclusion
- •References
- •Summary: Introduction
- •2.1 Introduction
- •Summary: Common Indications
- •2.2 Common Indications
- •2.2.1 Basal Cell Carcinoma (BCC)
- •2.2.2 Squamous Cell Carcinoma (SCC)
- •Summary: Uncommon Indications
- •2.3 Uncommon Indications
- •2.3.2 Microcystic Adnexal Carcinoma (MAC)
- •2.3.3 Atypical Fibroxanthoma (AFX)
- •2.3.5 Malignant Fibrous Histiocytoma (MFH)
- •2.3.6 Sebaceous Carcinoma (SC)
- •2.3.7 Melanoma
- •2.3.8 Merkel Cell Carcinoma (MCC)
- •Summary: Conclusion
- •2.4 Conclusion
- •References
- •3: Preoperative Evaluation
- •Summary: Introduction
- •3.1 Introduction
- •3.3 History of Present Illness and Physical Examination
- •Summary: Past Medical History
- •3.4 Past Medical History
- •Summary: Medications and Allergies
- •3.5 Medications and Allergies
- •Summary: Assessing the Need for Infection Prophylaxis
- •Summary: Discussion of Postoperative Care
- •3.7 Discussion of Postoperative Care
- •Summary: Conclusion
- •3.8 Conclusion
- •References
- •Summary: Introduction
- •4.1 Introduction
- •Summary: Mohs Surgery Waiting Room
- •4.2 Mohs Surgery Waiting Room
- •4.3 Mohs Surgery Operative Room Planning
- •4.3.1 Photography
- •4.3.2 Laser Safety
- •4.4 Mohs Surgery Operative Room Equipment
- •4.4.1 Surgical Table
- •4.4.3 Surgical Lights
- •4.4.4 Surgical Sink
- •4.4.5 Electrosurgical Equipment
- •4.4.6 Suction
- •4.4.7 Mayo Stand/Kick Bucket
- •4.4.8 Waste Disposal
- •Summary: Personal Protective Equipment
- •4.5 Personal Protective Equipment
- •4.5.1 Masks and Eye Protection
- •4.5.2 Gowns
- •4.5.3 Scrubs
- •4.5.4 Gloves
- •Summary: Instrumentation and Setup
- •4.6 Instrumentation and Setup
- •4.6.1 Scalpels
- •4.6.2 Blades
- •4.6.3 Standard Mohs Surgery Setup
- •4.6.4 Mohs Surgery Eye Tray
- •4.6.5 Excision/Closure Tray for Face
- •4.6.6 Excision/Closure Tray for Trunk
- •4.6.7 Nail Surgery Instruments
- •Summary: Wound Care Dressing Materials
- •4.7 Wound Care Dressing Materials
- •Summary: Equipment Sterilization
- •4.8 Equipment Sterilization
- •Summary: Monitoring and Emergency Equipment
- •4.9 Monitoring and Emergency Equipment
- •Summary: Conclusion
- •4.10 Conclusion
- •References
- •Summary: Introduction
- •5.1 Introduction
- •Summary: History
- •5.2 History
- •Summary: Pharmacology
- •5.3 Pharmacology
- •Summary: Pharmacokinetics
- •5.4 Pharmacokinetics
- •Summary: Regional Anesthesia
- •5.5 Regional Anesthesia
- •Summary: Peripheral Nerve Fibers
- •5.6 Peripheral Nerve Fibers
- •Summary: Metabolism
- •5.7 Metabolism
- •Summary: Toxicity
- •5.8 Toxicity
- •Summary: Method of Injection
- •5.9 Method of Injection
- •Summary: Amino-Esters
- •5.10 Amino-Esters
- •Summary: Amino-Amides
- •5.11 Amino-Amides
- •5.11.1 Topical Anesthesia
- •Summary: Conclusion
- •5.12 Conclusion
- •References
- •Summary: Introduction
- •6.1 Introduction
- •Summary: Scalp and Forehead
- •6.2 Scalp and Forehead
- •6.2.1 Vasculature
- •6.2.2 Nerves
- •6.2.3 Lymphatic Drainage
- •Summary: Midface
- •6.3 Midface
- •6.3.1 Nasal Subunit
- •6.3.1.1 Vasculature
- •6.3.1.2 Nerves
- •6.3.1.3 Lymphatic Drainage
- •6.3.2 Perioral
- •6.3.2.1 Vasculature
- •6.3.2.2 Nerves
- •6.3.2.3 Lymphatic Drainage
- •6.3.3 Chin
- •6.3.3.1 Vasculature
- •6.3.3.2 Nerves
- •6.3.3.3 Lymphatic Drainage
- •Summary: Periorbital
- •6.4 Periorbital
- •6.4.1 Vasculature
- •6.4.2 Nerves
- •6.4.3 Lymphatic Drainage
- •Summary: Cheeks
- •6.5 Cheeks
- •6.5.1 Vasculature
- •6.5.2 Nerves
- •6.5.3 Lymphatic Drainage
- •Summary: Auricular
- •6.6 Auricular
- •6.6.1 Vasculature
- •6.6.2 Nerves
- •6.6.3 Lymphatic Drainage
- •Summary: Neck
- •6.7 Neck
- •6.7.1 Nerves
- •6.7.2 Lymphatic Drainage
- •6.8 Special Anatomic Considerations in Mohs Micrographic Surgery
- •6.8.1 Danger Zones
- •6.8.2 Other Considerations
- •References
- •7: Mohs Surgery: Fixed Tissue Technique
- •Summary
- •Summary: Conclusion
- •7.2 Conclusion
- •References
- •8: Fresh Tissue Technique
- •Summary: Introduction
- •8.1 Introduction
- •Summary: The Technique
- •8.2 The Technique
- •Summary: Histologic Preparation of the Tissue
- •8.3 Histologic Preparation of the Tissue
- •Summary: Conclusion
- •8.4 Conclusion
- •References
- •Summary: Introduction
- •9.1 Introduction
- •Summary: Solid Organ Transplant Recipients
- •9.2 Solid Organ Transplant Recipients
- •Summary: HIV/AIDS
- •9.3 HIV/AIDS
- •Summary: Cutaneous Neoplasms
- •9.4 Cutaneous Neoplasms
- •9.4.1 Actinic Keratoses and Squamous Cell Carcinoma
- •9.4.2 Basal Cell Carcinoma
- •9.4.3 Melanoma
- •9.4.4 Merkel Cell Carcinoma
- •9.4.5 Kaposi Sarcoma
- •9.5.1 Preoperative Evaluation
- •9.5.2 Antibiotic Prophylaxis
- •9.5.3 Wound Healing
- •9.5.4 Selection of Therapeutic Modality
- •9.5.5 Follow-Up
- •Summary: Conclusion
- •9.6 Conclusion
- •References
- •10: Mohs Micrographic Surgery in Ethnic Skin
- •10.1 Introduction
- •Summary: Histologic Differences in Skin of Color
- •Summary: Basal Cell Carcinoma (BCC)
- •10.3 Basal Cell Carcinoma (BCC)
- •Summary: Squamous Cell Carcinoma (SCC)
- •10.4 Squamous Cell Carcinoma (SCC)
- •Summary: Malignant Melanoma (MM)
- •10.5 Malignant Melanoma (MM)
- •Summary: Conclusion
- •10.7 Conclusion
- •References
- •Summary: The Operating Room (OR)
- •11.2 The Operating Room (OR)
- •Summary: Surgical Waiting Room
- •11.3 Surgical Waiting Room
- •Summary: The Histopathology Laboratory
- •11.4 The Histopathology Laboratory
- •Summary: Grossing and Inking
- •11.5 Grossing and Inking
- •11.6 Embedding and Mounting Tissue and the Cryostat
- •Summary: Staining Frozen Sections
- •11.7 Staining Frozen Sections
- •Summary: Slide Reading
- •11.8 Slide Reading
- •Summary: Conclusion
- •11.10 Conclusion
- •References
- •Summary: Tissue Transport
- •12.1 Tissue Transport
- •Summary: Initial Processing
- •12.2 Initial Processing
- •Summary: Conclusion
- •12.3 Conclusion
- •Reference
- •Summary: Introduction
- •13.1 Introduction
- •13.2 Histopathologic Scanning of Mohs Slides
- •13.3 Histopathologic Recognition of Cutaneous Structures
- •13.3.1 Recognition of Epidermal and Epithelial Components and Their Neoplasia
- •13.3.1.1 The Epidermis
- •13.3.1.2 Melanocytes and the Melanocytic Lesions
- •13.3.1.4 The Pilosebaceous Unit
- •13.3.1.5 The Bulge
- •13.3.1.6 The Mantle and Sebaceous Glands
- •13.3.1.7 The Folliculocentric Basaloid Proliferations (FBP)
- •13.3.2 Histopathologic Recognition of Dermal Components
- •13.3.2.1 Fibrous Tissue, Desmoplasia, and Nerves
- •13.3.2.2 The Dermal Microvascular Unit
- •13.3.2.3 Dermal Muscles, Cartilage, and Subcutaneous Adipose Tissue
- •Summary: Conclusion
- •13.4 Conclusion
- •References
- •Summary: History
- •14.1 History
- •Summary: Preexamination Process
- •14.4 Preexamination Process
- •Summary: Examination Process
- •14.5 Examination Process
- •Summary: Postexamination Process
- •14.6 Postexamination Process
- •Summary: Conclusion
- •14.7 Conclusion
- •References
- •15: Immunostains
- •Summary: Introduction
- •15.1 Introduction
- •Summary: Melanoma
- •15.3 Melanoma
- •15.4 Basal Cell and Squamous Cell Carcinoma
- •Summary: Other Rare Tumors
- •15.7 Other Rare Tumors
- •15.7.1 Granular Cell Tumor
- •15.7.2 Primary Mucinous Carcinoma
- •15.7.3 Trichilemmal Carcinoma
- •Summary: Conclusions
- •15.8 Conclusions
- •References
- •16: Basal Cell Carcinoma
- •Summary: Introduction
- •16.1 Introduction
- •Summary: Etiology
- •16.2 Etiology
- •16.3 Histological Findings Using Horizontal Frozen Sections
- •Summary: Non-cancerous Conditions That May Be Histologically Similar to BCC
- •Summary: Cancerous Conditions That May Be Histologically Similar to BCC
- •16.6 Adnexal Differentiation Observed in BCC
- •Summary: Basosquamous Differentiation
- •16.7 Basosquamous Differentiation
- •Summary: Therapeutic Options
- •16.8 Therapeutic Options
- •Summary: Mohs Micrographic Surgery
- •16.9 Mohs Micrographic Surgery
- •Summary: Conclusions
- •16.10 Conclusion
- •References
- •17: Squamous Cell Carcinoma
- •Summary: Introduction
- •17.1 Introduction
- •Summary: Pathophysiology (Risk Factors for SCC Development)
- •17.2 Pathophysiology (Risk Factors for SCC Development)
- •17.2.1 Ultraviolet Light
- •17.2.2 Human Papilloma Virus
- •17.2.3 Molecular and Genetic Factors Impacting SCC Development
- •Summary: Clinical Disease Spectrum
- •17.3 Clinical Disease Spectrum
- •17.3.1 Actinic Keratosis
- •17.3.2 Squamous Cell Carcinoma In Situ
- •17.3.3 Invasive Squamous Cell Carcinoma
- •17.3.4 Differential Diagnosis
- •17.4 Management of Invasive Cutaneous SCC
- •17.4.1 Surgical Options
- •17.4.2 Radiation Therapy as Primary Therapy
- •17.5.4 Surgical Management
- •17.5.5 Radiation as Primary Therapy
- •17.5.6 Adjuvant Therapy
- •17.5.7 Assessment of Immune Status
- •17.5.8 Follow-Up for High-Risk SCC Patients
- •Summary: Treatment of Field Cancerization
- •17.6 Treatment of Field Cancerization
- •Summary: Conclusions
- •17.7 Conclusions
- •References
- •Summary: Introduction
- •18.1 Introduction
- •Summary: Surgical Treatment of Melanoma
- •18.2 Surgical Treatment of Melanoma
- •Summary: MMS for Cutaneous Melanoma
- •18.3 MMS for Cutaneous Melanoma
- •Summary: Application of MMS for the Treatment of Cutaneous Melanoma: IHC Stains
- •18.4 Application of MMS for the Treatment of Cutaneous Melanoma
- •18.4.1 IHC Stains
- •18.4.2 Technical Application of MMS and Interpretation of IHC Stains
- •Summary: Conclusion
- •18.5 Conclusion
- •References
- •19.1 Introduction
- •Summary: Epidemiology
- •19.2 Epidemiology
- •Summary: Pathogenesis
- •19.3 Pathogenesis
- •Summary: Clinical Features
- •19.4 Clinical Features
- •Summary: Pathology
- •19.5 Pathology
- •Summary: Differential Diagnose
- •19.6 Differential Diagnoses
- •Summary: Management
- •19.7 Management
- •19.7.1 Surgery
- •19.7.1.1 Wide Local Excision
- •19.7.1.2 Mohs Micrographic Surgery
- •19.7.2 Radiotherapy
- •19.7.3 Molecularly Targeted Therapy
- •19.7.4 Imaging Studies
- •Summary: Prognosis
- •19.8 Prognosis
- •Summary: Conclusion
- •19.9 Conclusion
- •20: Microcystic Adnexal Carcinoma
- •Summary: Introduction
- •20.1 Introduction
- •Summary: Epidemiology
- •20.2 Epidemiology
- •Summary: Pathogenesis
- •20.3 Pathogenesis
- •Summary: Clinical Features and Diagnosis
- •20.4 Clinical Features and Diagnosis
- •Summary: Histopathological Features
- •20.5 Histopathological Features
- •Summary: Treatment
- •20.6 Treatment
- •Summary: Prognosis and Follow-Up
- •References
- •21: Atypical Fibroxanthoma
- •Summary: History
- •21.1 History
- •Summary: Pathogenesis
- •21.2 Pathogenesis
- •Summary: Clinical Features
- •21.3 Clinical Features
- •Summary: Pathology
- •21.4 Pathology
- •Summary: Treatment
- •21.5 Treatment
- •Summary: Conclusion
- •21.6 Conclusion
- •References
- •22: Extramammary Paget Disease
- •Summary: Introduction
- •22.1 Introduction
- •Summary: History of EMPD and Epidemiology
- •22.2 History of EMPD and Epidemiology
- •22.2.1 History of EMPD
- •22.2.2 Epidemiology
- •22.2.3 Associated Malignancies
- •22.2.4 Affected Areas: Sites with Apocrine Glands
- •22.3 Clinical Presentation and Natural History
- •22.3.1 Clinical Presentation
- •22.3.2 Prognosis
- •Summary: Clinical Subtypes
- •22.4 Clinical Subtypes
- •22.4.1 Vulvar EMPD
- •22.4.2 Perianal EMPD
- •22.4.3 Penoscrotal EMPD
- •22.4.4 Triple EMPD
- •22.4.5 Unifocal or Multifocal Disease?
- •22.5 Diagnosing EMPD/Disease Pathophysiology
- •22.5.1 Histology
- •22.5.2 Histologic Differential Diagnosis
- •22.5.3 Evaluation for Internal Malignancy
- •22.5.4 Sentinel Lymph Node Biopsy
- •22.5.5 Pathophysiology
- •22.5.6 Cell of Origin
- •Summary: EMPD Treatment
- •22.6 EMPD Treatment
- •22.6.1 Wide Local Excision and Recommended Margin
- •22.6.2 Time to Recurrence
- •22.6.2.1 Mohs Surgery for EMPD
- •22.6.3 Mohs Surgery with CK7 Immunostaining
- •22.6.4 Peripheral Mohs Surgery
- •22.6.5 Scouting Biopsies
- •Summary: Alternative Treatment Options
- •22.7 Alternative Treatment Options
- •22.7.2 Photodynamic Therapy
- •22.7.3 Laser Vaporization
- •22.7.4 Radiation Therapy
- •22.7.5 Chemotherapy for EMPD: Local and Systemic
- •Summary: Conclusion
- •22.8 Conclusion
- •References
- •23: Leiomyosarcoma
- •Summary: Introduction
- •23.1 Introduction
- •Summary: Clinical Features
- •23.2 Clinical Features
- •Summary: Histologic Features
- •23.3 Histologic Features
- •Summary: Prognosis
- •23.4 Prognosis
- •23.4.1 Treatment
- •23.4.2 Mohs Micrographic Surgery (MMS)
- •Summary: Conclusion
- •23.5 Conclusion
- •References
- •24: Merkel Cell Carcinoma
- •Summary: Overview of Merkel Cell Carcinoma
- •24.1 Overview of Merkel Cell Carcinoma
- •Summary: Diagnosis of Merkel Cell Carcinoma
- •24.2 Diagnosis of Merkel Cell Carcinoma
- •24.2.1 Clinical Features
- •24.2.2 Pathology
- •24.2.3 Differential Diagnosis
- •Summary: Management of Merkel Cell Carcinoma
- •24.3 Management of Merkel Cell Carcinoma
- •24.3.1 Patient Evaluation and Staging
- •24.3.1.1 No Clinical Nodal Involvement
- •24.3.1.2 Clinical Nodal Involvement
- •24.3.1.3 Metastatic Disease
- •24.3.2 Treatment
- •24.3.3 Prognosis
- •24.4 Mohs Micrographic Surgery and Merkel Cell Carcinoma
- •Summary: Conclusion
- •24.5 Conclusion
- •References
- •25: Selected Sweat Gland Carcinomas
- •Summary: Porocarcinoma
- •25.1 Porocarcinoma
- •Summary: Hidradenocarcinoma
- •25.2 Hidradenocarcinoma
- •Summary: Cutaneous Adenoid Cystic Carcinoma
- •25.3 Cutaneous Adenoid Cystic Carcinoma
- •Summary: Malignant Cylindroma
- •25.5 Malignant Cylindroma
- •Summary: Mucinous Carcinoma of the Skin
- •25.6 Mucinous Carcinoma of the Skin
- •Summary: Conclusion
- •25.7 Conclusion
- •References
- •Porocarcinoma
- •Hidradenocarcinoma
- •Cutaneous Adenoid Cystic Carcinoma
- •Spiradenocarcinoma
- •Malignant Cylindroma
- •Mucinous Carcinoma of the Skin
- •26: Sebaceous Carcinoma
- •Summary: Introduction
- •26.1 Introduction
- •26.1.1 Origin
- •26.1.2 History
- •26.1.3 Extraorbital Sites
- •26.1.4 Incidence
- •Summary: Demographics
- •26.2 Demographics
- •26.2.1 Age, Sex, Irradiation, Race
- •26.2.3 Human Papillomavirus (HPV)
- •26.2.4 Other Risk Factors
- •Summary: Clinical Presentation
- •26.3 Clinical Presentation
- •Summary: Histopathology
- •26.4 Histopathology
- •26.4.1 Pattern of Differentiation
- •26.4.2 Degree of Differentiation
- •26.4.3 Mechanisms of Invasion
- •26.4.3.1 Direct Invasion
- •26.4.3.2 Pagetoid Spread
- •26.4.3.3 Multicentric Origin
- •26.4.4 Clinicopathologic Features of Poor Outcomes
- •Summary: Treatment
- •26.5 Treatment
- •26.5.1 Biopsy Procedure
- •26.5.2 Conjunctiva Mapped Biopsies
- •26.5.3 Oil Red O and Sudan Black Stains
- •26.5.4 Traditional Wide Local Excision (WLE)
- •26.5.5 Mohs Micrographic Surgery
- •26.5.6 Surgical and Tissue Processing Issues
- •26.5.7 Frozen Sections
- •26.5.9 Exenteration
- •26.5.10 Mohs Surgery, Practical Points
- •26.5.11 Corneal Protection Measures
- •Summary: Follow-Up Considerations
- •26.6.1 Local Recurrence
- •26.6.2 Metastasis
- •26.6.3 Distant Metastasis
- •26.6.4 Sentinel Lymph Node (SLN)
- •Summary: Conclusion
- •26.7 Conclusion
- •References
- •Summary: Introduction
- •27.1 Introduction
- •Summary: Review of the Relevant Anatomy
- •27.2 Review of the Relevant Anatomy
- •27.3 Anatomical Considerations When Using Mohs Micrographic Surgery in the Periorbital Region
- •Summary: Periorbital BCC
- •27.4 Periorbital BCC
- •Summary: Periorbital SCC
- •27.5 Periorbital SCC
- •Summary: Other Tumors
- •27.6 Other Tumors
- •Summary: Conclusion
- •27.7 Conclusion
- •References
- •28.1 Introduction
- •Summary: Introduction
- •Summary: Anatomy
- •28.2 Anatomy
- •28.2.1 Nail Matrix
- •28.2.2 Nail Plate
- •28.2.3 Supporting Portion: Nail Bed and Phalangeal Bone
- •28.2.4 Nail Folds
- •28.2.5 Cuticle
- •28.2.6 Hyponychium
- •28.2.7 Arteries and Nerves of the Digit
- •28.2.8 Extensor Tendon
- •Summary: Tumors
- •28.3 Tumors
- •28.3.1 Squamous Cell Carcinoma
- •28.3.3 Melanoma
- •28.3.4 Basal Cell Carcinoma
- •28.3.5 Warts
- •Summary: Mohs Technique
- •28.4 Mohs Technique
- •28.4.1 Preoperative Evaluation
- •28.4.2 Anesthesia
- •28.4.3 Instruments
- •28.4.4 Preoperative Preparation
- •28.4.5 Mohs Technique
- •28.4.6 Dressings and Postoperative Care
- •Summary: Complications
- •28.5 Complications
- •Summary: Conclusions
- •28.6 Conclusions
- •References
- •29: Genitalia
- •Summary: Introduction
- •29.1 Introduction
- •Summary: Surgical Technique
- •29.2 Surgical Technique
- •Summary: Reconstruction
- •29.3 Reconstruction
- •Summary: Common Genital Lesions Treated with Mohs Micrographic Surgery
- •29.4.1 Basal Cell Carcinoma
- •29.4.3 In Situ and Invasive Malignant Melanomas
- •29.4.6 Granular Cell Tumor
- •29.4.8 Leukemias and Lymphoblastomas
- •29.4.9 Langerhans Cell Histiocytosis
- •29.4.10 Haemolymphangioma
- •Summary: Conclusions
- •29.5 Conclusions
- •References
- •Summary: Introduction
- •30.1 Introduction
- •Summary: Innervation of the Face and Scalp
- •30.2 Innervation of the Face and Scalp
- •30.2.2 Sensory Innervation of the Face and Scalp
- •30.2.3 Innervation of the Ear
- •Summary: Muscles of Facial Expression
- •30.3 Muscles of Facial Expression
- •30.3.1 Muscles of the Forehead
- •30.3.2 Muscles of the Periorbital Region
- •30.3.3 Muscles of the Nose
- •30.3.4 Muscles of the Cheek and Perioral Region
- •30.4 Soft Tissue Components of the Scalp and Face
- •30.4.1 Scalp
- •30.4.2 Face
- •30.5 Bony and Cartilaginous Structures of the Face and Scalp
- •30.5.1 Bony Landmarks
- •30.5.2 Cartilaginous Structures
- •30.6 Muscosa of the Lip, Nose, and Conjunctiva
- •Summary: Conclusion
- •30.8 Conclusion
- •References
- •Summary: Bleeding Complications
- •31.1 Bleeding Complications
- •Summary: Infectious Complications
- •31.2 Infectious Complications
- •Summary: Nerve Injury
- •31.3 Nerve Injury
- •Summary: Tumor Recurrence
- •31.4 Tumor Recurrence
- •Summary: Medication Complications
- •31.5 Medication Complications
- •Summary: Recently Described Complications
- •31.6 Recently Described Complications
- •Summary: Conclusion
- •31.7 Conclusion
- •References
- •32.1.1 Upper Eyelid
- •32.1.1.1 Primary Closure
- •32.1.1.2 Myocutaneous Advancement Flap
- •32.1.1.3 Full-Thickness Skin Graft
- •32.1.2 Lower Eyelid
- •32.1.2.1 Primary Closure
- •32.1.2.2 Myocutaneous Advancement Flap
- •32.1.2.3 Ellipse Sliding Flap
- •32.1.2.4 Unipedicle Flap
- •32.1.2.5 Skin Graft
- •Summary: Full-Thickness Eyelid Defects
- •32.2.1 Upper Eyelid
- •32.2.1.1 Primary Closure
- •32.2.2 Lower Eyelid
- •32.2.2.1 Primary Closure
- •Summary: Special Circumstances
- •32.3 Special Circumstances
- •32.3.1 Medial Canthal Defect
- •32.3.1.1 Glabellar Flap
- •Summary: Postoperative Care and Follow-up
- •Summary: Conclusion
- •32.5 Conclusion
- •References
- •33: Flaps
- •Summary: Introduction
- •33.1 Introduction
- •Summary: Risks and Precautions
- •33.2 Risks and Precautions
- •Summary: Flap Design and Execution
- •33.3 Flap Design and Execution
- •Summary: Advancement Flaps
- •33.4 Advancement Flaps
- •33.4.1 Single Advancement
- •33.4.2 Bilateral Advancement
- •33.4.3 Crescentic Advancement
- •33.4.4 Island Pedicle
- •Summary: Rotation Flaps
- •33.5 Rotation Flaps
- •33.5.1 Dorsal Nasal Rotation
- •33.5.2 Bilateral Rotation
- •Summary: Transposition Flaps
- •33.6 Transposition Flaps
- •33.6.1 Rhombic
- •33.6.1.1 Dufourmental
- •33.6.1.2 Thirty-Degree Angle Webster Flap
- •33.6.2 The Banner Flap
- •33.6.3 Bilobed Flap
- •Summary: Interpolation Flaps
- •33.7 Interpolation Flaps
- •33.7.1 Paramedian Forehead
- •33.7.2 Nasolabial Interpolation
- •33.7.4 Retroauricular
- •Summary: Postoperative Care
- •33.8 Postoperative Care
- •Summary: Complications
- •33.9 Complications
- •Summary: Monitoring and Follow-Up
- •33.10 Monitoring and Follow-Up
- •Summary: Conclusion
- •33.11 Conclusion
- •References
- •34: Skin Grafting
- •Summary: Introduction
- •34.1 Introduction
- •Summary: Physiology
- •34.2 Physiology
- •Summary: Indications
- •34.3 Indications
- •Summary: Preoperative Assessment
- •34.4 Preoperative Assessment
- •Summary: Site Selection
- •34.5 Site Selection
- •Summary: Full-Thickness Skin Grafts
- •34.6.1 Graft Harvesting
- •34.6.2 Graft Fixation
- •Summary: Split-Thickness Skin Grafts
- •34.7.1 Graft Harvest
- •34.7.2 Graft Fixation
- •Summary: Composite Grafts
- •34.8 Composite Grafts
- •Summary: Postoperative Instructions
- •34.9 Postoperative Instructions
- •34.9.1 FTSG
- •34.9.2 STSG
- •Summary: Cultured Skin Substitutes
- •34.10 Cultured Skin Substitutes
- •34.10.1 Epidermal
- •34.10.2 Dermal
- •34.10.3 Bilayered
- •34.10.4 Graft Fixation
- •34.10.5 Postoperative Instructions
- •Summary: Graft Failure
- •34.11 Graft Failure
- •Summary: Conclusion
- •34.12 Conclusion
- •References
- •Summary: Introduction
- •35.1 Introduction
- •Summary: Side to Side Closures
- •35.2 Side to Side Closures
- •Summary: Suturing of the Wounds
- •35.3 Suturing of the Wounds
- •Summary: Cosmetic Subunits
- •35.4 Cosmetic Subunits
- •Summary: Complex Facial Defects
- •35.5 Complex Facial Defects
- •Summary: General Considerations
- •35.6 General Considerations
- •Summary: Complications
- •35.7 Complications
- •Summary: Conclusion
- •35.8 Conclusion
- •References
- •36: Prosthetic Rehabilitation
- •Summary: Introduction
- •36.1 Introduction
- •Summary: Moulage Impression Procedure
- •36.2 Moulage Impression Procedure
- •Summary: Adhesive Retained Nasal Prosthesis
- •36.3 Adhesive Retained Nasal Prosthesis
- •Summary: Adhesive Retained Auricular Prosthesis
- •36.4 Adhesive Retained Auricular Prosthesis
- •Summary: Adhesive and/or Mechanically Retained Orbital Prosthesis
- •36.5 Adhesive and/or Mechanically Retained Orbital Prosthesis
- •36.6 Midface/Multisite Craniofacial Prosthesis
- •36.7 Considerations Regarding Implant Retained Craniofacial Prosthesis
- •Summary: Implant Retained Nasal Prosthesis
- •36.8 Implant Retained Nasal Prosthesis
- •Summary: Implant Retained Auricular Prosthesis
- •Summary: Implant Retained Orbital Prosthesis
- •36.10 Implant Retained Orbital Prosthesis
- •36.11 Multisite Implant Retained Craniofacial Prosthesis
- •Summary: Conclusion
- •36.12 Conclusion
- •References
- •Summary: Adjuvant Treatment with Imiquimod
- •37.1 Adjuvant Treatment with Imiquimod
- •Summary: Adjuvant Treatment with Radiation
- •37.2 Adjuvant Treatment with Radiation
- •37.3 Nonsurgical Treatment of Aggressive Basal Cell Carcinoma
- •Summary: Photodynamic Therapy
- •37.5 Photodynamic Therapy
- •Summary: Off-Label Intraoperative PDT with Topical and Intralesional Aminolevulinic Acid on SCC of the Penis
- •Summary: Conclusion
- •37.7 Conclusion
- •References
- •References
- •39: Establishing a Mohs Practice
- •Summary: General Considerations
- •39.1 General Considerations
- •Summary: The Electronic Medical Record
- •39.2 The Electronic Medical Record
- •39.3 Credentials, Licensure, and Malpractice Insurance
- •Summary: Quality Assurance
- •39.4 Quality Assurance
- •Summary: Cameras
- •39.5 Cameras
- •Summary: Care of Instruments
- •39.6 Care of Instruments
- •Summary: Work Rooms
- •39.7 Work Rooms
- •Summary: Microscopes
- •39.8 Microscopes
- •Summary: Instrumentation
- •39.9 Instrumentation
- •Summary: Regulations
- •39.10 Regulations
- •Summary: Reception Area
- •39.11 Reception Area
- •Summary: Waiting Area
- •39.12 Waiting Area
- •Summary: Exam/Surgery Rooms
- •39.13 Exam/Surgery Rooms
- •Summary: Nurses Work Station
- •39.15 Nurses Work Station
- •Summary: Personnel
- •39.16 Personnel
- •Summary: The Laboratory
- •39.17 The Laboratory
- •Summary: Space
- •39.18 Space
- •Summary: Personal Protective Equipment
- •39.19 Personal Protective Equipment
- •Summary: Mapping and Grossing the Tissue
- •39.20 Mapping and Grossing the Tissue
- •Summary: Devices to Aid Embedding
- •39.22 Devices to Aid Embedding
- •Summary: Cryosectioning Tissue
- •39.23 Cryosectioning Tissue
- •Summary: Staining
- •39.24 Staining
- •Summary: Coverslipping
- •39.25 Coverslipping
- •Summary: At the End of the Day
- •Summary: Permanent Sections and Immunostains
- •39.27 Permanent Sections and Immunostains
- •39.27.1 Immunostains
- •Summary: Training of Laboratory Technicians
- •39.28 Training of Laboratory Technicians
- •Summary: Inspections and Regulations
- •39.29 Inspections and Regulations
- •Summary: Marketing
- •39.30 Marketing
- •Summary: Preoperative Consultation
- •39.31 Preoperative Consultation
- •Summary: Brochures and Handouts
- •39.32 Brochures and Handouts
- •Summary: Operative Consents
- •39.33 Operative Consents
- •Summary: Conclusion
- •39.34 Conclusion
- •Reference
- •Summary: The Brazilian Perspective
- •40.1 The Brazilian Perspective
- •Summary: The Argentinean Perspective
- •40.2 The Argentinean Perspective
- •Summary: Conclusion
- •40.3 Conclusion
- •References
- •References
- •42.1 Characteristics of Skin Cancers in East Asia
- •Summary: Treatment of Skin Cancers in East Asia
- •42.2 Treatment of Skin Cancers in East Asia
- •42.2.1 Standard Treatment of Skin Cancers
- •42.2.2 Present State of MMS in East Asia
- •Summary: Conclusion
- •42.3 Conclusion
- •References
- •43.1 Introduction and Brief History of Mohs Micrographic Surgery in Australia and New Zealand
- •43.2 Work Practices of Australian Mohs Surgeons
- •43.2.1 Background
- •43.2.2 Mohs Caseload
- •43.2.3 Conclusion
- •Summary: The Australian Mohs Database
- •43.3 The Australian Mohs Database
- •43.3.1 Introduction
- •43.3.3 Squamous Cell Carcinoma Treated with Mohs Micrographic Surgery in Australia
- •43.3.4 Conclusion
- •43.4.1 Mohs for Invasive SCC and SCC In Situ of the Nail Apparatus
- •43.4.2 Extensive Use of Secondary Wound Healing in a Knowledgeable Patient
- •Summary: Mohs Surgery in New Zealand
- •43.5 Mohs Surgery in New Zealand
- •Summary: Conclusions
- •43.6 Conclusions
- •References
- •Summary: Introduction
- •44.1 Introduction
- •Summary: Patient Safety Considerations
- •44.2 Patient Safety Considerations
- •44.2.1 The Preoperative Visit
- •44.2.2 Past Medical History and Physical Exam
- •Summary: Information for Patients
- •44.3 Information for Patients
- •44.3.1 Cardiovascular Complications
- •44.3.2 Antibiotic Prophylaxis
- •44.3.3 Anticoagulation
- •44.3.4 Anesthesia
- •44.3.5 Allergies
- •Summary: Planning for the Surgical Day
- •44.4 Planning for the Surgical Day
- •44.5.1 Patient Emergencies
- •44.5.2 Staff Safety
- •44.5.3 Mohs Lab Safety
- •Summary: Conclusion
- •44.6 Conclusion
- •References
- •Summary: Introduction
- •45.1 Introduction
- •Summary: The Four Elements
- •45.2 The Four Elements
- •Summary: Standard of Care
- •45.3 Standard of Care
- •Summary: Clinical Guidelines
- •45.4 Clinical Guidelines
- •Summary: Legal Relevance
- •45.5 Legal Relevance
- •Summary: Case Example 1
- •45.6 Case Example 1
- •Summary: Case Example 2
- •45.7 Case Example 2
- •Summary: Ethical Relevance
- •45.8 Ethical Relevance
- •45.8.1 Actinic Keratoses
- •45.8.1.1 Invasive Techniques
- •Cryosurgery
- •Curettage and Electrodessication
- •Dermabrasion and Chemical Peels
- •Carbon Dioxide or Erbium:YAG Laser Ablation
- •45.8.1.2 Non-invasive Techniques
- •Topical Chemotherapy
- •Photodynamic Therapy (PDT)
- •References
- •Summary: Introduction
- •46.1 Introduction
- •Summary: Medical Malpractice
- •46.2 Medical Malpractice
- •46.2.1 Duty
- •46.2.2 Breach of Duty
- •46.2.3 Causation
- •46.2.4 Damages
- •Summary: Consent/Refusal for Treatment
- •46.3 Consent/Refusal for Treatment
- •46.3.1 Implied Consent
- •46.3.2 Express Consent
- •46.3.3 Informed Consent
- •46.3.3.2 Reasonable Patient Standard/Legal Standard
- •Summary: Medical Records
- •46.4 Medical Records
- •46.5 Complications in Skin Cancer Treatment
- •Summary: Rectifying Adverse Events: Key Steps
- •46.6 Rectifying Adverse Events: Key Steps
- •46.6.1 Build Trust
- •46.6.2 Take an Active Role
- •46.6.3 Help the Patient
- •46.6.4 Enlist Help from Others
- •46.6.5 Be Available
- •46.6.6 Contact the Malpractice Carrier
- •46.6.7 Preserve Evidence
- •46.6.8 Document the Facts of the Event
- •Summary: Conclusion
- •46.7 Conclusion
- •References
- •Summary: Introduction
- •47.1 Introduction
- •47.3 The Potential Detrimental Impact of Mohs Surgery
- •47.3.4 Negative Self-Image
- •47.4.1 Social Phobia
- •47.4.2 Generalized Anxiety Disorder
- •47.4.3 Depression
- •Summary: Conclusion
- •47.5 Conclusion
- •References
- •Index
428 |
J.M. Sheehan and T.E. Rohrer |
|
|
The pedicle of the Abbé flap should not be circumferentially wrapped but kept moist with occlusive ointment. As with other interpolation flaps, the pedicle will remain in place for at least 3 weeks. During this time, the oral aperture will be significantly distorted, and the patient must be counseled. The pedicle is divided and the final repair takes place, again with careful attention to the placement of the vermillion borders.
33.7.4 Retroauricular
The retroauricular flap is a two-staged interpolation flap useful for large defects of the helix. Defects in this location typically involve the perichondrium and are not suitable for grafts. This flap is considered a random flap as it is not based on a large named artery. It is harvested from the richly vascularized skin of the postauricular scalp and is advanced over intervening intact skin to fill the helical defect; the pedicle remains attached to the posterior scalp. The flap should be thinned to match the depth of the defect and carefully sewn into place. The pedicle is circumferentially dressed, and the patient is warned of likely postoperative bleeding and discomfort. The donor site is not repaired until pedicle take-down and often, due to its inconspicuous location, is allowed to heal secondarily.
Summary: Postoperative Care
•Meticulous postoperative wound care is necessary to ensure an optimal outcome. Verbal and written instructions regarding home wound care should be reviewed and then provided in writing to the patient. A pressure dressing should be applied and left intact for 24–48 h. It is important that the wound be kept clean, moist, and covered until suture removal. This will eliminate desiccation, promote reepithelialization, reduce bacterial contamination, and aid in hemostasis.
of infection. Meticulous intraoperative hemostasis and good postoperative compression dressings are very important in minimizing postoperative bleeding. A pressure dressing should be applied and left intact for 24–48 hours This dressing includes a layer of ointment applied directly to the wound, nonstick bandage such as Telfa, gauze for pressure, and surgical tape. Finally, elastic dressing materials, such as Flexinet or Coban, may be helpful for wounds on the scalp or extremities.
For any type of aforementioned procedure or repair, it is important that the wound be kept clean, moist, and covered until suture removal. This will eliminate desiccation, promote reepithelialization [23], reduce bacterial contamination, and aid in hemostasis. Verbal instructions regarding home wound care should be reviewed and then provided in writing to the patient. After removal of the pressure dressing, the wound should be cleaned once or twice daily with attention to gentle removal of any crust and debris that may have formed. This is followed by a layer of ointment. A bland, non-medicated ointment, such as petrolatum or Aquaphor is preferred over bacitracin or Neosporin. The use of topical antibiotics following cutaneous surgery increases the risk of contact dermatitis [24] without imparting a significant reduction in infection rates [25].
The signs and symptoms of hemorrhage and wound infection should be reviewed as early intervention can reduce serious complications. To minimize nonemergency calls, however, it is helpful to educate the patient as to what to expect during normal wound healing. The patient should be provided with the physician’s contact information and should be encouraged to call with any questions or concerns.
Summary: Complications
•Complications include bleeding and hematoma, discomfort and pain, infection, flap necrosis, trapdoor deformity, hypertrophic scar, atrophic scar, erythema, and telangiectasias. Precautions should be taken to minimize these risks, and treatment options exist.
33.8Postoperative Care
Meticulous postoperative wound care is necessary to ensure an optimal outcome. Attention must be made to limit postoperative bleeding of all surgical wounds, particularly flaps, as hemorrhage or hematoma formation may jeopardize tissue survival and increase the risk
33.9Complications
Early complications of Mohs surgery and all types of closure are bleeding, pain, and infection. Bleeding typically occurs in the first 24 hours after surgery and must be addressed promptly. Low-flow ooze may be treated
33 Flaps |
429 |
|
|
Before |
After |
Fig. 33.20 (a) Post-operative erthema and telangiectasia after linear repair of right upper cheek; (b) after treatment with pulsed dye laser
by compression. Patients should be instructed to apply direct pressure for at least 20 minutes without peeking to see if it is working. Frank arterial hemorrhage or large hematoma formation will require partial or complete suture removal, evacuation of clot, and exploration of the wound to allow visualization and closure of the bleeding vessel. Patients should be instructed to call if they see an enlarging mass below or around the wound.
Signs of infection usually occur within the first week after surgery and include increased pain, erythema, and heat around the wound, purulent and sometimes foul-smelling drainage, and fever. When wound infection is suspected, a culture must be obtained for pathogen identification and antibiotic susceptibility, and treatment with a broad-spectrum antibiotic should be initiated. Methicillin-resistant Staphylococcus aureus (MRSA) infections are increasing dramatically in frequency and should always be considered in the case of wound infections [26].
In the early postoperative period, partial or complete flap necrosis may occur. This may be due to inadequate blood supply from the wound bed, which is more commonly encountered in smokers, or when an underlying hematoma is present. Flap design may also lead to vascular compromise and flap necrosis, as when the pedicle is too narrow to support the mass of the flap, when there is too much torque, or when there is too much tension at the flap’s leading edge. Areas of partial necrosis will heal secondarily and may lead to a less appealing scar which can be revised after wound healing is complete.
Later in the postoperative period, a trapdoor deformity may occur in which the center of the flap becomes elevated and the suture line becomes depressed. It may resolve spontaneously over a period of 6–12 months. However, if the trapdoor effect or pin-cushioning persists, it may respond to intralesional steroids, flap elevation with flap thinning, and/or resurfacing. The trapdoor effect may be prevented with wide undermining around the primary defect, proper thinning of the flap, proper sizing of the flap, and the use of a geometric shape for the flap.
An expected consequence of surgery is the formation of a scar. While the goal of reconstructive surgery is to minimize the appearance of the resultant scar, at times they may widen or even become hypertrophic. With time, hypertrophic scars tend to flatten and soften. Their course may be hastened with the administration of intralesional steroids and laser treatment. In areas under tension and/or motion, such as the upper back and arms over the deltoids, scars may spread or become atrophic. While scar spread may become less noticeable with time as the initial dark-pink color fades, the width generally does not change significantly. Erythema and telangiectasia often form around scars during the healing phase and may persist for extended periods of time. Highly vascular areas (rosacea) and those under high tension are more likely to develop persistent erythema and telangiectasia. This can be effectively treated with lasers, such as the pulsed dye laser, KTP, or intense pulsed light (Fig. 33.20).
430 |
J.M. Sheehan and T.E. Rohrer |
|
|
Summary: Monitoring and Follow-Up
•Follow-up is required for suture removal, as well as to evaluate outcomes and potential complications and to intervene as necessary.
intraoperative technique and postoperative wound care are necessary to ensure an optimal outcome. Patients should be seen for follow-up to monitor for potential complications, evaluate outcomes, and employ necessary treatments or interventions.
33.10 Monitoring and Follow-Up
If nonabsorbable epidermal sutures are placed, the patient should return for suture removal at the appointed time. Typically, sutures on the face and neck are removed at postoperative day 7, while sutures elsewhere on the body are removed at 10–14 days. It is helpful to see the patient after 4–6 weeks for fol- low-up to evaluate outcomes and any necessary interventions.
Summary: Conclusion
•The elements to successful flap execution include proper patient selection and preparation, comprehension of risks and necessary precautions, as well as proper postoperative wound care and patient education. There are several subtypes and variations of each flap type, and each has an important role in dermatologic surgery.
33.11 Conclusion
The planning and execution of repair following Mohs surgery vary from case to case. The creation of a flap should be considered when simpler closures are not ideal. The elements to successful flap execution include proper patient selection and preparation, comprehension of risks and necessary precautions, use of sterile or clean technique, informed procedure design and meticulous suture technique, as well as proper postoperative wound care and patient education. Flaps are commonly classified according to their primary movement – advancement flaps, rotation flaps, transposition flaps, and interpolation flaps. There are several subtypes and variations of each flap type, and each has an important role in dermatologic surgery. Meticulous
References
1. Berg JW, Appelbaum PS, Lidz CW, Parker LS. Informed consent: legal theory and clinical practice. 2nd ed. New York: Oxford University Press; 2001.
2. Chang LK, Whitaker DC. The impact of herbal medicines on dermatologic surgery. Dermatol Surg. 2001;278:759–63.
3. Futoryan T, Grande D. Postoperative wound infection rates in dermatologic surgery. Dermatol Surg. 1995;21(6):509–14.
4. Dixon AJ, Dixon MP, Askew DA, Wilkinson D. Prospective study of wound infections in dermatologic surgery in the absence of prophylactic antibiotics. Dermatol Surg. 2006; 32(6):819–26; discussion 826–817.
5.Milton SH. Pedicled skin-flaps: the fallacy of the length: width ratio. Br J Surg. 1970;57(7):502–8.
6. Daniel RK, Williams HB. The free transfer of skin flaps by microvascular anastomoses. An experimental study and a reappraisal. Plast Reconstr Surg. 1973;52(1):16–31.
7. Stell PM. The pig as an experimental model for skin flap behaviour: a reappraisal of previous studies. Br J Plast Surg. 1977;30(1):1–8.
8.Chilukuri S, Leffell D. Basic principles of flap reconstruction. In: Cook JL, Rohrer TE, Nguyen TH, Mellette JR, edi-
tors. Flaps and grafts in dermatologic surgery. London: Elsevier; 2007.
9. Fazio MJ, Zitelli JA. Flaps. In: Ratz JL, Geronemus RG, Goldman MP, et al., editors. Textbook of dermatologic surgery. Philadelphia: Lippincott-Raven; 1998. p. 225–7.
10. Heniford BW, Bailin PL, Marsico Jr RE. Field guide to local flaps. Dermatol Clin. 1998;16(1):65–74.
11.Dzubow LM. Flap dynamics. J Dermatol Surg Oncol. 1991;17(2):116–30.
12.Antia NH, Buch VI. Chondrocutaneous advancement flap
for the marginal defect of the ear. Plast Reconstr Surg. 1967; 39(5):472–7.
13. Mellette Jr JR, Harrington AC. Applications of the crescentic advancement flap. J Dermatol Surg Oncol. 1991;17(5): 447–54.
14. Dzubow LM, Lambert RW. A dorsal nasal advancement flap for off midline defects. J Am Acad Dermatol. 2004;50(3): 380–3.
15.Tomich JM, Wentzell JM, Grande DJ. Subcutaneous island pedicle flaps. Arch Dermatol. 1987;123(4):514–8.
16.Dzubow LM. The dynamics of flap movement: effect of pivotal restraint on flap rotation and transposition. J Dermatol Surg Oncol. 1987;13(12):1348–53.
17.Rieger RA. A local flap for repair of the nasal tip. Plast Reconstr Surg. 1967;40(2):147–9.
18.Limberg AA. Design of local flaps. Mod Trends Plast Surg. 1966;2:38–61.
19.Bray DA. Clinical applications of the rhomboid flap. Arch Otolaryngol. 1983;109(1):37–42.
33 Flaps |
431 |
|
|
20.Masson JK, Mendelson BC. The banner flap. Am J Surg. 1977;134(3):419–23.
21.Zitelli JA. The bilobed flap for nasal reconstruction. Arch Dermatol. 1989;125(7):957–9.
22.Schulte DL, Sherris DA, Kasperbauer JL. The anatomical basis of the Abbe flap. Laryngoscope. 2001;111(3):382–6.
23.Eaglstein WH. Moist wound healing with occlusive dressings: a clinical focus. Dermatol Surg. 2001;27(2):175–81.
24. Gette MT, Marks Jr JG, Maloney ME. Frequency of postoperative allergic contact dermatitis to topical antibiotics. Arch Dermatol. 1992;128(3):365–7.
25. Smack DP, Harrington AC, Dunn C, Howard RS, Szkutnik AJ, Krivda SJ, et al. Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial. JAMA. 1996; 276(12):972–7.
26. Cruse PJ, Foord R. The epidemiology of wound infection. A 10-year prospective study of 62,939 wounds. Surg Clin North Am. 1980;60(1):27–40.
